2014
Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011
Butts SF, Owen C, Mainigi M, Senapati S, Seifer DB, Dokras A. Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011. Fertility And Sterility 2014, 102: 1041-1047.e1. PMID: 25086790, PMCID: PMC4184996, DOI: 10.1016/j.fertnstert.2014.06.043.Peer-Reviewed Original ResearchMeSH KeywordsChi-Square DistributionEmbryo Culture TechniquesEmbryo TransferFemaleHumansInfertility, FemaleLive BirthLogistic ModelsOdds RatioOvarian ReservePregnancyPregnancy RatePrimary Ovarian InsufficiencyRegistriesRetrospective StudiesRisk FactorsSperm Injections, IntracytoplasmicTime FactorsTreatment OutcomeUnited StatesConceptsDiminished ovarian reserveIntracytoplasmic sperm injectionElevated FSHLive birthsOvarian reserveART cyclesSperm injectionAssisted Reproductive Technology Clinic Outcome Reporting System databaseClinical pregnancy rateRetrospective cohort studyLive birth rateReproductive technology outcomesAssisted reproduction cyclesCombination of ICSIReporting System databaseCohort studyPrimary diagnosisImproved outcomesPregnancy rateMAIN OUTCOMELower oddsDiminished oddsFSHOnly indicationTechnology outcomes
2012
Diagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates
Butts SF, Ratcliffe S, Dokras A, Seifer DB. Diagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates. Fertility And Sterility 2012, 99: 382-388.e7. PMID: 23102859, PMCID: PMC3561490, DOI: 10.1016/j.fertnstert.2012.09.026.Peer-Reviewed Original ResearchConceptsLive birth rateAge 40 yearsART cyclesART coverageElevated FSHOvarian reserveTreatment outcomesReproductive technology treatment outcomesSpecific infertility diagnosisState insurance coverageReproductive technology cyclesDiminished ovarian reserveProportion of cyclesCross-sectional studyBirth rateReporting System databaseInsurance mandatesMix of patientsProvider factorsInfertility diagnosisMAIN OUTCOMEFSHSignificant associationTreatment prognosisAdditional studies
2011
Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels
Buyuk E, Seifer DB, Younger J, Grazi RV, Lieman H. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertility And Sterility 2011, 95: 2369-2372. PMID: 21497340, DOI: 10.1016/j.fertnstert.2011.03.071.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersChi-Square DistributionEmbryo TransferFemaleFertilization in VitroFollicle Stimulating Hormone, HumanFollicular PhaseHumansInfertility, FemaleNew YorkOocyte RetrievalOvulationOvulation InductionPregnancyPregnancy RateRetrospective StudiesTime FactorsTreatment OutcomeUp-RegulationConceptsAnti-Müllerian hormoneNumber of oocytesClinical pregnancy rateSerum AMH levelsDiminished ovarian reserveAMH levelsFSH levelsDay 3 embryosElevated FSHOvarian responseART cyclesPregnancy rateEarly follicular FSH levelsFollicle-stimulating hormone levelsSerum anti-Müllerian hormoneCycle cancellation rateSerum FSH levelsReproductive technology programCycle cancellationOvarian reserveRetrospective studyHormone levelsMAIN OUTCOMECancellation rateRandom sera